Tumor Necrosis Factor-α Gene Polymorphism (G-308A) and Dilated Cardiomyopathy

Abstract

The issue that genetic polymorphism of tumor necrosis factor-α (TNF-α) is associated with dilated cardiomyopathy (DCM) is debatable. We sought to investigate the potential role of TNF-α gene polymorphism (G-308A) in the susceptibility to dilated cardiomyopathy. We retrieved PubMed, EMBASE, and CNKI to collect all articles which reported on the association between TNF-α G-308A polymorphism and dilated cardiomyopathy. Two authors used the Newcastle-Ottawa Scale (NOS) checklist to assess the quality of the included studies. The odds ratio (OR) with 95% confidence intervals (CI) were pooled in a specific genetic model to assess the association and Stata version 14.0 software was used. A total of 9 studies with 1338 patients and 1677 controls were included in this study. The results from this meta-analysis indicated that TNF-α G-308A polymorphism significantly increased the risk of dilated cardiomyopathy in heterozygous comparison (GA versus GG: OR = 1.87; 95%CI = 1.03-3.40; P < 0.05). The increased risk of DCM was also found in Asian populations using a dominant model and heterozygous comparison (GA+AA versus GG: OR = 2.00, 95%CI = 1.02-3.92, P < 0.05; GA versus GG: OR = 1.94, 95%CI = 1.23-3.06, P < 0.05). The current meta-analysis revealed that TNF-α gene polymorphism (G-308A) may be associated with the susceptibility to DCM.

Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy

“…Tumor necrosis factor-α is a pro-inflammatory cytokine produced by activated macrophages and monocytes. Different studies have demonstrated the role of TNF-α in the pathophysiology of atherosclerosis, myocardial infarction and chronic heart failure [ 35 , 36 , 37 ]. Elevated TNF-α levels have also been found in patients with DCM, which indicates that TNF-α may be related to the pathogenesis of dilated cardiomyopathy [ 36 ].…”

“…Based on all these data, a recent metanalysis, which included nine eligible studies (1338 patients and 1677 controls), evaluated the possible association between TNF-α gene polymorphism (G-308A) and susceptibility to DCM. The main result of this metanalysis is that TNF-α gene polymorphism (G-308A) may have an important role in the pathogenesis and progression of dilated cardiomyopathy, especially in Asian populations [ 35 ]. However, to date, there are no studies on the implications of TNF-α in risk stratification of patients with DCM.…”

The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy

“…To confirm that, TNF-α was used as a treatment and resulted in a dose-and time-dependent decrease in mRNA levels of dystrophin and titin (40). Other studies supported this hypothesis, where they revealed that TNFα gene polymorphism (G-308A) might play a key role in the susceptibility to dilated cardiomyopathy (41).…”